We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pioneering Microscopy Technique Improves Diagnosis of Glioblastoma Brain Tumors

By LabMedica International staff writers
Posted on 16 Oct 2024

Along the brain’s largest nerve fiber highway, known as the corpus callosum, travel cells that form one of the most lethal brain cancers, glioblastomas. More...

Now, scientists have developed a cellular detector by integrating artificial intelligence (AI) with a cutting-edge microscope, enabling them to visualize and monitor specific cells with unprecedented clarity in deep brain tissue, including along this superhighway. The researchers believe that understanding the early ‘traffic patterns’ of cancer cells along the corpus callosum could aid in establishing a biomarker for the earlier detection of glioblastomas in patients, potentially enhancing future diagnostic tools.

This collaborative endeavor between EMBL (Heidelberg, Germany) and Heidelberg University (Heidelberg, Germany) builds upon a new microscopy technique developed by EMBL researchers in 2021 in association with colleagues from Germany, Austria, Argentina, China, France, the United States, India, and Jordan. The EMBL team worked with these diverse partners to tackle some of the challenges neuroscientists encounter when studying deep brain regions. Previously, the diffuse nature of brain tissue made it challenging for scientists to observe neurons and glial cells, such as astrocytes, and to investigate their communication within the cortex. This difficulty extended to visualizing neural cells in the hippocampus, another deep brain area critical for spatial memory and navigation. The researchers' new method utilized advanced microscopy techniques that offered a broader and clearer view while compensating for the distortion caused by scattered light waves in deep brain tissue.

Now, in a study published in the journal Nature Communications, the EMBL researchers collaborated with neuroscientists, neurooncologists, and AI specialists to enhance this microscope further. The outcome is a device capable of observing living neurons and other brain cell types deep within the brain over extended periods. Glioblastomas are predominantly a white-matter disease. The new advanced imaging technique allowed the team to study these tumor cells within their microenvironment in the white matter. This capability was vital for understanding how tumor cells invade the densely myelinated (insulated) fiber “lanes” of the corpus callosum and subsequently adapt and spread throughout the brain. This invasion is also linked to the critical structures of the brain that glioblastomas invade in a lethal manner.

A key aspect of this recent collaboration was the integration of AI, which helped to reduce noise in the images, resulting in much clearer contrast. The AI can differentiate various structures within the white matter, such as myelinated fibers and blood vessels, which is significant for multiple reasons. A tailored workflow enabled the researchers to separate blood vessel signals from those of the myelinated neural fibers, clarifying the microenvironment of the tumor cells. As a result, the researchers identified a potential microscopic imaging biomarker associated with the structural characteristics of the white matter microenvironment. This innovative workflow paves the way for identifying imaging patterns for glioblastomas, allowing for earlier detection than currently possible. Their next steps involve integrating additional advanced imaging modalities to create practical tools for standard clinical applications.

“These findings also help explain the current challenges in detecting glioblastoma cells at the tumor’s infiltrative edges using conventional MRI techniques, which are the standard in clinical imaging,” said Varun Venkataramani at the Neurology Clinic of the University Hospital Heidelberg. “As a neuroscientist, neurologist, and neurooncologist, I see potential for this technology to bridge the gap between laboratory research and clinical application, improving how we could diagnose and potentially treat brain tumors.”

 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.